Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Plus Radiotherapy in Poor Prognosis LA-NSCLC
NCT00673738Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2008
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Median Progression Free Survival at 36 months. Started Apr 2008; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00673738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673738.